Skip to main navigation
Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • History
  • Product
  • Pipeline
    • AD Agitation
    • AD Psychosis
    • Rett syndrome
    • Schizophrenia – Negative Symptoms
    • Major Depressive Disorder
    • Scientific Publications
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Mission & Values
    • Total Rewards
    • Recruiting Agencies
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Major Depressive Disorder
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Total Rewards
    • Recruiting Agencies

Media Center

Recent News

12/04/19
Summary ToggleACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
11/25/19
Summary ToggleACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
11/11/19
Summary ToggleACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
11/04/19
Summary ToggleACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
10/30/19
Summary ToggleACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
2019 | 2018 | 2017 | Archive
icon-information1

Company Information

Annual Report

SCIENTIFIC

Media Statements

ACADIA Pharmaceuticals Responds to False and Misleading Claims About NUPLAZID 

  • COMPANY FACTS
  • ACADIA is a biopharmaceutical company focused on addressing unmet medical needs in central nervous system disorders
  • Headquartered in San Diego, California
  • R&D Center, Princeton, New Jersey
  • Stock is listed on NASDAQ: ACAD
  • Chief Executive Officer:
    Stephen R. Davis
  • Media Contact

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Share
  • Privacy
  • Terms
  • Email

© 2019 ACADIA Pharmaceuticals Inc. ACADIA and NUPLAZID are registered trademarks of
ACADIA Pharmaceuticals Inc. All rights reserved.